| Entry |
|
|---|
| Name |
Trastuzumab (genetical recombination) (JAN);
Trastuzumab (INN);
Herceptin (TN)
|
|---|
| Product |
|
|---|
| Sequence |
(Heavy chain) EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA
PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCSRWG
GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP
KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW
YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS
KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG
(Disulfide bridge: 22-96; 147-203; 264-324; 370-428, Dimer: 229; 232)
(Light chain) DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP
GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP EDFATYYCQQ HYTTPPTFGQ
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ
ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: 23-88; 134-194; H223-L214, Dimer) |
|---|
| Type |
Peptide |
|---|
| Activity |
|
|---|
| Remark |
Therapeutic category: ATC code: |
|---|
| Comment |
breast cancer treatment
Monoclonal antibody
|
|---|
| Target |
ERBB2 tyrosine kinase (HER2) [HSA: 2064] [KO: K05083] |
|---|
| Pathway |
|
|---|
| Interaction |
Genomic biomarker: HER2 [HSA: 2064] overexpression
 |
|---|
| Structure map |
| Antineoplastics - protein kinases inhibitors |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D03257 Trastuzumab (genetical recombination) (JAN); Trastuzumab (INN)
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XC Monoclonal antibodies
L01XC03 Trastuzumab
D03257 Trastuzumab (genetical recombination) (JAN); Trastuzumab (INN)
Target-based classification of drugs [BR:br08310]
Cytokine receptors
Receptor tyrosine kinase
RTK class I (EGF receptor family)
ERBB2 tyrosine kinase [HSA:2064] [KO:K05083]
Trastuzumab [ATC:L01XC03]
D03257 Trastuzumab (genetical recombination) (JAN); Trastuzumab (INN)
Antineoplastics [BR:br08308]
Molecularly targeted agents
Monoclonal antibody
Trastuzumab [ATC:L01XC03]
D03257 Trastuzumab (genetical recombination) (JAN); Trastuzumab (INN)
 |
|---|
| Other DBs |
CAS: 180288-69-1 PubChem: DrugBank: NIKKAJI: |
|---|
